NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Samaritan Pharmaceuticals, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

SP-01A Provides HIV Patients Improved Quality of Life - The effective treatment of HIV-infected patients is also compromised by the toxicity of approved regimens, conferred resistance, and cross-resistance. SP-01A, currently in development, represents a significant step forward in HIV treatment
SP-01A Provides HIV Patients Improved Quality of Life

 

NewswireToday - /newswire/ - Las Vegas, NV, United States, 2008/02/12 - The effective treatment of HIV-infected patients is also compromised by the toxicity of approved regimens, conferred resistance, and cross-resistance. SP-01A, currently in development, represents a significant step forward in HIV treatment. OTC BB: SPHC.OB

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Source: Medical News Papers, Inc.
By Lynne Jeter

Despite tremendous advances in recent years in the field of antiretroviral (ARV) therapy, the Human Immunodeficiency Virus’s (HIV) ability to mutate and develop resistance to these drugs poses a significant problem for treatments that are already in use and those in the pipeline.

The effective treatment of HIV-infected patients is also compromised by the toxicity of approved regimens, conferred resistance, and cross-resistance. These developments are of particular concern in developing countries, where 95 percent of all cases of HIV are diagnosed.

Las Vegas-based Samaritan Pharmaceuticals’ HIV oral entry inhibitor, SP-01A, currently in development, represents a significant step forward in HIV treatment. Used with any existing anti-retroviral drug, SP-01A creates a firewall around healthy cells that prevents HIV entry.

“At present, a number of drugs on the market do an incredible job extending life expectancies of patients with HIV,” explained Dr. Janet Greeson, CEO of Samaritan Pharmaceuticals, Inc. “However, these drugs do not address myriad serious side effects,” which kidney stones; nausea; vomiting; diarrhea; increased cholesterol, triglycerides, and glucose; headaches; weakness; blurred vision; dizziness; rashes; low platelets; hair loss; and anemia.

Unlike currently approved antiretroviral therapies, SP-01A, the only oral entry inhibitor in its class, conditions the cell membrane as opposed to targeting the virus or its receptors directly.

In a 30-patient, 8-week study, SP-01A demonstrated proof of concept with significance in two crucial areas: a viral log drop of 1.32 (virus undetectable, with no adverse events), and improved quality of life. In fact, SP-01A was the only drug of its kind in clinical trials to demonstrate improved patient quality of life, according to Whalen Scale indices.

“HIV patients’ QOL (quality of life) is usually based on their viral load and CD4 parameters and side effects from their ARVs,” Greeson pointed out. “Patients with high viral loads and low CD4 counts usually experience opportunistic infections where HIV weakens the immune system, making the body more susceptible to other infections, such as fungal, bacterial, viral, parasitic infections and pneumonias. Therefore, a new HIV treatment that lowers viral load, increases CD4 counts, and adds no addition side-effect burden, where the majority of current antiretroviral treatments do add side effects, would be of great benefit to the improvement of an HIV patient’s QOL.”

New HIV drugs should develop a new way to block entry of the HIV virus into the CD4 cell while not adding any safety burden, noted Greeson.

“One way to accomplish this is to create a firewall in the CD4 cell by modifying the cell content to resist HIV viral entry and enhance the effect of current HIV therapies,” she said. “Currently, all the drugs on the market attack the virus at different mechanisms of action after cell entry. The virus is extremely tricky and finds new ways to counter punch these drugs. By creating a firewall to prevent cell entry, you wouldn’t even have to enter the ring to battle HIV.”

In addition to SP-01A, Samaritan has SP-10 and SP-03, which are new molecules that have similar mechanisms of action in preventing viral entry into healthy cells.

“It’s possible that in the near future, a drug will be developed that will block the entry of the HIV virus in to CD4 cells throughout the body, including crossing the BBB (blood brain barrier) allowing for current and future HIV treatments to kill the circulating virus, thus allowing the body’s immune system to respond and tackle HIV and not be overwhelmed,” said Greeson. “My vision is that a person could control HIV (so that) no new virus is able to enter and the killer HIV treatments would be able to knock out the virus so a person might be virus free as long as they were taking the treatment -- similar to insulin with diabetes. In addition, one could envision a ‘day-after cocktail,’ which could be used to contain and kill the virus before it has a chance to take hold and over come the immune response.”

SP-01A has been used concomitantly with most HIV antiretrovirals in Phase I/II clinical studies and found to enhance the effect of the HIV drugs used significantly, “a mean 1.3 log10 decrease in viral load,” detailed Greeson. “Upon completion of Phase II/III clinical studies, SP-01A would be submitted for FDA approval. Therefore, we target commercialization in about two to three years.”

Samaritan is collaborating with Pharmaplaz to develop and commercialize SP-01A.

Last year, Samaritan was honored with the 2006 North American Frost & Sullivan Award Technology Innovation Award in the field of HIV drug development in recognition of the company’s effort in developing this antiviral therapy-based drug.

About Samaritan Pharmaceuticals
Samaritan Pharmaceuticals: "Transforming Today's Science Into Tomorrow's Cures...''
Samaritan Pharmaceuticals (samaritanpharma.com) is an entrepreneurial biopharmaceutical company committed to bringing innovative life-saving drugs to suffering patients.

Disclaimer
The company disclaims any information created by an outside party and endorses only information communicated by its press releases, filings, and website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science, and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-Q filed November 19, 2007. The company undertakes no duty to update forward-looking statements.

Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth / Erica Ruderman / Rachel Colgate
P: 212-825-3210

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Samaritan Pharmaceuticals, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


SP-01A Provides HIV Patients Improved Quality of Life

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Kristi Eads - SamaritanPharma.com 
702-735-7001 kristieads[.]samaritanpharma.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Samaritan Pharmaceuticals, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Samaritan Pharmaceuticals, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Adds Another Program into its Pre-clinical R&D Oncology Pipeline through An Exclusive Worldwide Collaboration with Accent Therapeutics
Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with its AI Immunology Platforms
Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™
DSM to Acquire First Choice Ingredients to Accelerate Growth in Food and Beverage
STEMCELL Technologies Launches Human Pluripotent Stem Cell Characterization and Banking Services in Partnership with WiCell
Biocon Selects TrackWise to Enable Enterprise Quality Management Across Global Biopharmaceutical Operations
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
Ipsen Strengthens its Pre-clinical Oncology Pipeline with An Exclusive Worldwide-collaboration with BAKX Therapeutics, Inc. for BKX-001
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe Finds Frost & Sullivan
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease
Exelixis and Ipsen Announce Cabozantinib in Combination with An Immune Checkpoint Inhibitor Significantly Improved Progression
Ipsen Opts-in to Join Exelixis with Ongoing Development of Cabometyx® for People Living with A Form of Thyroid Cancer
Antibiotic Alternatives Stimulate New Product Development in Global Animal Feed Ingredient Market Finds Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Mokuyobi





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)